Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 9, 2006, Pages 520-526

  Simons, W R ^a   Vinod, H D ^b   Gerber, R A ^c   Bolinder, B ^d  

^a Global Health Economics and Outcomes Research Inc   (United States)

^b FORDHAM UNIVERSITY   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d SANOFI   (France)

Author keywords

Diabetes diagnosis; Diabetes related complications; HbA1c; Insulin therapy; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; MIGLITOL; SULFONYLUREA;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET THERAPY; EXERCISE; FEMALE; GERMANY; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 33845312601     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951779     Document Type: Article

References (20)

1. Campbell R, White J, Jr. Insulin therapy in type 2 diabetes. J Am Pharm Assoc 2002; 42: 602-611
2. Dietlin G, Schroder-Bernhardi D. Use of the mediplus patient database in healthcare research. Int J Clin Pharmacol Ther 2002; 40: 130-133
3. The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
4. Duggan AK. Modeling different approaches to the management of upper gastrointestinal disease. Pharmacoeconomics 1998; 14 (Suppl 2): 25-37
5. Eggleston A. Cost effectiveness of treatment for gastro-esophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998; 42: 13-16
6. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FDR, Martinez L, Ross S, Bolinder B, Stridde E. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28: 427-428
7. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-575
8. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 533-537
9. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of, and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 1995; 311: 293-295
10. Kennedy L Emerging treatments-glycemic control and beyond. In: Mazzaferri EL (ed.). Yearbook of Endocrinology pp13-16, Elsevier, Philadelphia, 2005
11. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26 (Suppl 3): S18-S24
12. Krobot KJ, Steinberg HW, Pfaffenrath V. Migraine prescription density and recommendations. Results of the PCAOM study. Cephalalgia 1999; 19: 511-519
13. Lawrenson R. Patterns of antidepressant prescription in general practice: lessons from the MediPlus database. Primary Care Psychiatry 1999; 5: 3-7
14. Morris A. The reality of type 2 diabetes treatment today. Int J Clin Pract Suppl 2001; 121: 32-35
15. Rathmann W, Haastert B, Roseman JM, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol 1999; 52: 1103-1109
16. Simons WR, Kemp R, Bolinder B. A five year longitudinal analysis of the health benefits of transitioning toward insulin therapy sooner in newly diagnosed type II diabetics. Value Health 3 2000, [no. 5]:DB3 (Abstract)
17. Stratton IM, Adler AI, Neil AW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 25): prospective observational study. BMJ 2000; 321: 405-412
18. Todd J. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 1999; 14: 1500-1505
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
20. Weyer C, Borgardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes. J Clin Invest 1999; 104: 787-794